NEUROLOGICAL TARGETS OF ANTIDEPRESSANTS IN C ELEGANS
线虫抗抑郁药的神经学靶标
基本信息
- 批准号:2891131
- 负责人:
- 金额:$ 14.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-08-01 至 2001-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (Adapted from applicant's abstract): The SSRI antidepressants,
including fluoxetine (Prozac), are the drugs most commonly prescribed for
treatment of depressive disorders. The in vivo targets of fluoxetine that
are responsible for its antidepressive effects and its side effects are not
well established. Systematically establishing such targets in the human or
in mammalian models of depression is not possible. We are using the
nematode Caenorhabditis elegans to identify mechanisms of fluoxetine action.
In preliminary studies we have established that fluoxetine has three
distinct effects in C. elegans. One of these effects is probably due to
blocking serotonin reuptake, as expected from one known target in mammals.
The other two effects appear not to involve serotonin. We have isolated
mutations in seven genes that confer resistance to one of the
non-serotonergic effects of fluoxetine (Nrf mutants). We have molecularly
cloned one of these genes, called nrf-6. nrf-6 encodes the defining member
of a family of multi-pass transmembrane proteins. We propose to investigate
nrf-6 by completing this initial molecular analysis and by determining its
expression pattern, subcellular localization, and site of function in
conferring fluoxetine sensitivity. We propose to clone two additional
fluoxetine resistance genes that we have identified and to perform similar
analyses as for nrf-6. We propose to continue mutagenesis screens to
identify other genes that mediate the nose contraction and other fluoxetine
responses. Finally, we propose to identify in mammals members of the new
nrf-6 family as a first step toward determining whether the
nematode-fluoxetine interaction might have direct relevance to humans.
描述(改编自申请人的摘要):SSRI抗抑郁药,
包括氟西汀(百忧解),是最常用的药物,
治疗抑郁症。 氟西汀的体内靶点,
负责其抗抑郁作用,其副作用不是
很好地建立了。 在人体内系统地建立这种靶点,
在哺乳动物抑郁症模型中是不可能的。 我们使用
线虫秀丽隐杆线虫,以确定氟西汀的作用机制。
在初步研究中,我们已经确定氟西汀有三个
在C.优美的 这些影响之一可能是由于
阻断5-羟色胺再摄取,正如哺乳动物中一个已知靶点所预期的那样。
另外两种效应似乎不涉及血清素。 我们已经分离出
七个基因的突变赋予了对其中一种
氟西汀(Nrf突变体)的非神经递质效应。 我们在分子水平上
克隆了其中一个基因,叫做nrf-6。 NRF-6编码限定元件
一个多通道跨膜蛋白家族的成员。 我们建议调查
通过完成这一初步的分子分析,并通过确定其
表达模式、亚细胞定位和功能位点,
赋予氟西汀敏感性。 我们建议克隆另外两个
氟西汀耐药基因,我们已经确定,并进行类似的
对nrf-6的分析。 我们建议继续进行诱变筛选,
确定其他基因介导的鼻子收缩和其他氟西汀
应答 最后,我们建议在哺乳动物中识别新的
NRF-6系列作为确定是否
线虫-氟西汀相互作用可能与人类直接相关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES H THOMAS其他文献
JAMES H THOMAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES H THOMAS', 18)}}的其他基金
TISSUE DOPPLER ASSESSMENT OF RIGHT VENTRICULAR PERFORMANCE IN ACUTE HEART FAI
急性心衰患者右心室性能的组织多普勒评估
- 批准号:
7608224 - 财政年份:2007
- 资助金额:
$ 14.94万 - 项目类别:
NEUROLOGICAL TARGETS OF ANTIDEPRESSANTS IN C ELEGANS
线虫抗抑郁药的神经学靶标
- 批准号:
2697306 - 财政年份:1998
- 资助金额:
$ 14.94万 - 项目类别:
IDENTIFICATION OF NEURAL DEGENERATION MUTANTS OF C. ELEGANS
线虫神经退行性突变体的鉴定
- 批准号:
6098458 - 财政年份:1998
- 资助金额:
$ 14.94万 - 项目类别:
NEUROLOGICAL TARGETS OF ANTIDEPRESSANTS IN C ELEGANS
线虫抗抑郁药的神经学靶标
- 批准号:
6186613 - 财政年份:1998
- 资助金额:
$ 14.94万 - 项目类别:
IDENTIFICATION OF NEURAL DEGENERATION MUTANTS OF C. ELEGANS
线虫神经退行性突变体的鉴定
- 批准号:
6234424 - 财政年份:1997
- 资助金额:
$ 14.94万 - 项目类别:
相似海外基金
Extending the utility and durability of antifungal agents via innovative treatment regimens that minimise drug resistance
通过创新治疗方案最大限度地减少耐药性,延长抗真菌药物的效用和持久性
- 批准号:
MR/Y002164/1 - 财政年份:2024
- 资助金额:
$ 14.94万 - 项目类别:
Research Grant
New approach based on enzyme stimulating of peptides for targeting drug resistance breast cancers
基于肽酶刺激的新方法用于靶向耐药性乳腺癌
- 批准号:
10713648 - 财政年份:2023
- 资助金额:
$ 14.94万 - 项目类别:
Functional and transcriptome analyses of protein kinases in Candida glabrata antifungal drug resistance
光滑念珠菌抗真菌药物耐药性中蛋白激酶的功能和转录组分析
- 批准号:
10643423 - 财政年份:2023
- 资助金额:
$ 14.94万 - 项目类别:
The role and mechanism of RNA m6A modification in the pathogenesis and drug-resistance of prostate cancer
RNA m6A修饰在前列腺癌发病及耐药中的作用及机制
- 批准号:
10638634 - 财政年份:2023
- 资助金额:
$ 14.94万 - 项目类别:
Mechanisms of HIV fitness and drug resistance inferred from high-resolution molecular dynamics and sequence co-variation models
从高分辨率分子动力学和序列共变模型推断出 HIV 适应性和耐药性的机制
- 批准号:
10750627 - 财政年份:2023
- 资助金额:
$ 14.94万 - 项目类别:
Reversing Drug Resistance in Tumors with Clickable Antibody Pairs
利用可点击的抗体对逆转肿瘤的耐药性
- 批准号:
10566266 - 财政年份:2023
- 资助金额:
$ 14.94万 - 项目类别:
Elucidation of prion strain-specific effect of antiprion drugs and drug resistance mechanisms
阐明抗朊病毒药物的朊病毒株特异性作用和耐药机制
- 批准号:
23H02828 - 财政年份:2023
- 资助金额:
$ 14.94万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mathematical Modeling of Drug Resistance Evolution and The Optimal Treatment Strategy in EGFR Mutated Lung Cancer
EGFR突变肺癌耐药演化的数学模型及最佳治疗策略
- 批准号:
22KJ0768 - 财政年份:2023
- 资助金额:
$ 14.94万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Targeting RAGE in tumor and TME to oppose inflammation and drug resistance in obesity associated ER+ breast cancer
靶向肿瘤和 TME 中的 RAGE,对抗肥胖相关 ER 乳腺癌的炎症和耐药性
- 批准号:
10734834 - 财政年份:2023
- 资助金额:
$ 14.94万 - 项目类别:
Targeting chromosomal insatiability for overcoming drug resistance
针对染色体不饱和性克服耐药性
- 批准号:
23K08200 - 财政年份:2023
- 资助金额:
$ 14.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)